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WHAT IS ALREADY KNOWN ABOUT
THIS SUBJECT
• Endothelin-A receptor antagonists (ETRAs)
and phosphodiesterase-type 5 inhibitors are
approved monotherapies for the treatment
of pulmonary arterial hypertension;
combining agents from these two drug
classes could be beneﬁcial.
• There is a signiﬁcant pharmacokinetic (PK)
interaction between the ETRA bosentan and
the phosphodiesterase-type 5 inhibitor
sildenaﬁl.
• This study assessed whether the ETRA
sitaxentan similarly impacts the PK of
sildenaﬁl.
WHAT THIS STUDY ADDS
• This study demonstrates that sitaxentan
has little effect on sildenaﬁl PK and
pharmacodynamics and that no dose
adjustment of either agent is required upon
co-administration of sildenaﬁl with
sitaxentan.
AIMS
This study evaluated the effects of sitaxentan on the
pharmacodynamic [systemic blood pressure (BP)] and pharmacokinetic
(PK) parameters of sildenaﬁl in healthy volunteers.
METHODS
Healthy subjects (18–60 years,n = 24) were randomized into two
sequence groups.Group 1 received sitaxentan sodium 100 mg daily
(7 days),followed by placebo (7 days).Group 2 received placebo
(7 days),followed by sitaxentan sodium 100 mg (7 days).On day 7 of
each treatment period,participants received sildenaﬁl 100 mg.PK
parameters and BP were analysed on day 7 in each treatment period.
RESULTS
Sildenaﬁl exposure was slightly higher [AUC• geometric mean ratio
(GMR),128%] when co-administered with sitaxentan 100 mg vs.
placebo,demonstrating a weak,but statistically signiﬁcant interaction
(90% conﬁdence interval 115.5%,141.2%).The mean maximum positive
(Emax+) and maximum negative (Emax–) changes from baseline in both
systolic and diastolic BP were comparable for sitaxentan and placebo
(range 4.8–7.3 mmHg) with three of four geometric mean ratios falling
within the equivalence window,suggesting that the drug interaction
was not clinically signiﬁcant.Adverse events were similar between
sitaxentan 100 mg (39%) and placebo (30%).No deaths or serious
adverse events occurred during the study.
CONCLUSION
The dose of sildenaﬁl does not need to be adjusted when co-
administered with sitaxentan.
Introduction
Pulmonary arterial hypertension is a progressive dis-
ease characterized by vasoconstriction and vascular
remodelling of small pulmonary arteries; increased
pulmonary artery pressure and vascular resistance
ultimately lead to failure of the right ventricle and
death. Endothelin receptor antagonists (ETRAs), such as
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inhibitors,such as sildenaﬁl,are approved monotherapies,
but combining drugs from different classes may provide
additive, potentially synergistic, effects [1]. This study
evaluated the effects of sitaxentan at steady state on
the pharmacokinetics (PK) of sildenaﬁl and its primary
metabolite N-desmethylsildenaﬁl after a single dose of
sildenaﬁl,as well as the effect on systemic blood pressure
(BP),in healthy volunteers.
Methods
This was a two-arm, double-blind, placebo-controlled,
randomized,crossover study in 24 healthy subjects 18–60
yearsofage.Subjectswererandomizedintotwosequence
groups.Group 1 received sitaxentan sodium 100 mg daily
(7 days), followed after a 14-day washout by placebo (7
days).Group 2 received placebo (7 days),followed 14 days
later by sitaxentan sodium 100 mg (7 days). On day 7 of
each treatment period, participants received sildenaﬁl
100 mg, concurrently with the sitaxentan dose.BP and PK
were analysed on day 7 in each treatment period.The pro-
tocol was approved by the Institutional Review Board for
the site (Bio-Kinetic Clinical Applications, Inc., Springﬁeld,
MO,USA)andthestudywasconductedinaccordancewith
the Declaration of Helsinki (2000), Good Clinical Practice
guidelines, according to the International Conference on
Harmonization of Technical Requirements for Registration
of Pharmaceuticals for Human Use Harmonized Tripartite
Guideline (1995),and all applicable federal,state and local
laws, rules and regulations.Written informed consent was
obtained from all subjects.
Bloodsamplesforthedeterminationofsitaxentancon-
centrations were collected prior to dosing on days 1,3 and
5 and for sitaxentan, sildenaﬁl and N-desmethylsildenaﬁl
predose,and at 0.25,0.5,1,1.5,2,2.5,3,3.5,4,6,8,10,12,16
and 24 (day 8) h post dose on day 7 of each treatment
period. Seated systolic and diastolic BP measurements
were taken predose (baseline) and at 0.5,1,1.5,2,3,4 and
6 h post dose on day 7 in both treatment periods.All mea-
surements were performed in triplicate at each time point,
and mean values reported.
Blood samples were collected into tubes containing
ethylenediamine tetraaceticacid, processed to plasma
by centrifugation, and stored (–20°C) until analysis
using liquid chromatography/tandem mass spectrometry
methods (sitaxentan: MDS Pharma Services, Montreal,
Canada;sildenaﬁl and N-desmethylsildenaﬁl:CEDRA Corp.,
Austin, TX, USA) validated to meet the speciﬁcations set
out in the Food and Drug Administration Bioanalytical
Method Validation guidance [2]. Analytes were extracted
by organic solvent extraction using isotopic internal
standardization. The mass transitions monitored were
m/z 475→58 (sildenaﬁl), m/z 461.5→283 (N-
desmethylsildenaﬁl) and m/z 453→417 (sitaxentan). The
analytical range, within-study assay precision (coefﬁcient
ofvariation)andaccuracywere5.00–750 ng ml
-1,3.5–4.4%
and 93.1–101.0% for sildenaﬁl; 2.00–300 ng ml
-1,4.9–7.6%
and 98.3–105.8% for N-desmethylsildenaﬁl; and 0.005–
2.0 mgm l
-1, 3.8–6.7% and 100.0–111.5% for sitaxentan.
Interference evaluations conducted prior to analysis
ensured that each analyte did not adversely inﬂuence the
quantiﬁcation of the other analytes.
Routine laboratory tests (haematology,clinical chemis-
try, urinalysis), physical examinations, vital signs and ECG
readings were conducted at screening and on day 8 of
each treatment period. At baseline, an additional physical
examinationandvitalsignscheckwasperformed,withthe
latter repeated multiple times throughout day 7. Adverse
events (AEs) and use of concomitant medications were
recorded.
PK parameters Cmax, Tmax, lz [ﬁrst-order rate constant
associated with the terminal (log-linear) portion of the
curve, estimated via linear regression of time vs. log con-
centration], t1/2, AUC over a 24-h dosing interval at steady
state (AUC0–24; sitaxentan), and AUC0–t and AUC• (sildenaﬁl
and N-desmethylsildenaﬁl) were calculated using non-
compartmental analysis. AUC0–t was calculated using the
linear trapezoidal method,where t is the time of last mea-
surable concentration. AUC0–• was calculated as AUC0–• =
AUC0–t + Ct/l.
Pharmacodynamic (PD) parameters were the
maximum positive change (Emax+), maximum negative
change(Emax–)andthemeanchange(Eavg)atallseventime
points in seated systolic and diastolic BP values.
PK calculations and statistical analyses used SAS for
Windows Version 9.1 (SAS Institute Inc., Cary, NC, USA).
Comparisons of sildenaﬁl and N-desmethylsildenaﬁl PK
parameters with respect to placebo and sitaxentan treat-
ments used an analysis of variance (ANOVA) model with
sequence,subject within sequence,treatment,and period
as the classiﬁcation variables. Conﬁdence intervals
(CI, 90%) were constructed for the treatment ratios
(sitaxentan to placebo) of all parameters using the
log-transformed data and the two one-sided t-tests
procedure.
The PD parameters (Emax+,Emin– and Eavg) for the change
from baseline (predose, day 7) systolic and diastolic BP
were compared between sitaxentan and placebo treat-
ments using the same ANOVA model with data on the origi-
nal scale. CIs (90%) were constructed for the treatment
ratios (sitaxentan to placebo) using the two one-sided
t-tests procedure.
Results
Twenty-four subjects were recruited and randomized
(Table 1). Twenty-two (92%) completed both treatment
periods and were included in the PK and PD analyses.
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N-desmethylsildenaﬁlgivenwitheitherplaceboorsitaxen-
tan 100 mg are shown in Table 2.
Sildenaﬁl mean plasma concentrations 3 and 10 h
post dose were slightly higher when co-administered
with sitaxentan 100 mg vs. placebo, resulting in an 18%
and 28% increase in mean Cmax and AUC•,respectively.For
both parameters the upper limits of the 90% CIs for
the geometric mean ratios (sitaxentan to placebo) were
outside the 80–125% equivalence window, indicat-
ing a statistically signiﬁcant interaction between the
two drugs, consistent with CYP3A4/5 inhibition. N-
desmethylsildenaﬁl Cmax and AUC• increased by 1 and 6%,
respectively, and were not statistically signiﬁcant. There
was no effect on sildenaﬁl or N-desmethylsildenaﬁl t1/2
values.
Mean systolic and diastolic BPs were similar after con-
comitantdosingofsildenaﬁl100 mgwitheithersitaxentan
100 mg or placebo. The mean maximum positive (Emax+)
and maximum negative (Emax–) changes from baseline in
both systolic and diastolic BP were comparable for sitax-
entan and placebo (range 4.8–7.3 mmHg), with three of
four geometric mean ratios falling within the equivalence
window. Mean average changes (Eavg) were very variable,
ranging from –0.07 ( 6.00) to 0.86 ( 5.14) and 1.92 (
5.18) to 0.65 ( 3.68) mmHg for systolic and diastolic BP,
respectively.
A similar proportion of subjects reported AEs during
dosing with sitaxentan 100 mg (39%) and with placebo
(30%),with headache as the most common (26% subjects
on sitaxentan and 30% on placebo, in all cases on day 7).
No AEs were related to hypotension.There were no clini-
cally signiﬁcant changes in laboratory tests.
Discussion
Co-administration of sitaxentan increased sildenaﬁl expo-
sure slightly,probably due to the weak inhibition by sitax-
entan of CYP3A4,the principal hepatic metabolic enzyme
for sildenaﬁl, but had no effect on N-desmethylsildenaﬁl
exposure.The effect of sildenaﬁl on sitaxentan PK was not
examined, but steady-state sitaxentan plasma concentra-
tions in the presence of sildenaﬁl were similar to steady-
state sitaxentan plasma concentrations from other PK
Table 1
Subject demographics
Parameter
Treatment
sequence 1
Treatment
sequence 2
(n = 12) (n = 12)
Age (years), median (range) 27.5 (21.0–47.0) 26.5 (19.0–50.0)
Male/female 10/2 11/1
Body mass index (kg m-2),
median (range)
25.0 (20.1–29.5) 26.1 (21.5–29.7)
White/Black or
African-American
11/1 11/1
Table 2
Pharmacokinetic parameters for sitaxentan, and sildenaﬁl and N-desmethylsildenaﬁl following administration of sildenaﬁl 100 mg after either sitaxentan
1 0 0m go rp l a c e b of o r7d a y s
Parameter* Sitaxentan 100 mg* Placebo*
Geometric mean ratio (%)†
Estimate 90% CI
Sildenaﬁl (n = 22)
Cmax (ng ml-1) 440  232 377  208 117.61 93.81, 147.46
AUC• (h ng-1 ml-1) 1648  692 1295  488 127.69 115.46, 141.22
t1/2 (h) 2.82  0.45 2.76  0.45 – –
Tmax (h)‡ 1.25 1.00 – –
AUC0–t (h ng-1 ml-1) 1575  671 1222  474 124.95 113.40, 137.68
N-desmethylsildenaﬁl (n = 22)
Cmax (ng ml-1) 104  40.8 109  53.1 100.70 82.72, 122.60
AUC• (h ng-1 ml-1) 425  115 440  112 105.78 96.21, 116.30
t1/2 (h) 5.14  2.13 5.13  1.63 – –
Tmax (h)‡ 1.00 1.00 – –
AUC0–t (h ng-1 ml-1) 389  105 372  107 112.43 98.50, 128.32
Sitaxentan (n = 22)
Cmax (mgm l -1) 10.2  4.73
AUC0–t (h mg-1 ml-1) 25.2  10.2
t1/2 (h) 8.42  1.46
Tmax (h)‡ 2.48
*Values are expressed as arithmetic mean  SD. †Statistical comparison of pharmacokinetic parameters between sitaxentan and placebo based on analysis of natural log-
transformed data. ‡Median. AUC, area under the plasma concentration–time curve (AUC0–t was calculated using the linear trapezoidal method where t is the time of last measurable
concentration. AUC0–• was calculated as AUC0–• = AUC0–t + Ct/l); CI, conﬁdence interval; Cmax, maximum plasma concentration; t1/2, elimination half-life; Tmax, time to maximum
plasma concentration.
PK and PD effects of sitaxentan on sildenaﬁl
Br J Clin Pharmacol / 69:1 / 25studies when sitaxentan was administered alone [3].Given
that there were no clinically relevant changes in BP and
single oral doses of sildenaﬁl are well tolerated up to
800 mg [4] the increased exposure to sildenaﬁl should not
be clinically relevant and no dose adjustment of either
agent is required upon co-administration of sildenaﬁl with
sitaxentan.
In contrast, combining the nonselective endothelin
receptor antagonist bosentan (125 mg day
-1) with sildena-
ﬁl (20–80 mg) decreased sildenaﬁl Cmax by 55.4% (90% CI
40.3,66.6); and conversely,after 6 days’ co-administration,
sildenaﬁl increased bosentan Cmax by 42.0% (90% CI 15.4,
74.8) [5,6].
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